Tel: 1-631-504-6093
Email:
Awesome Features1111

Slide Title 2

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas pulvinar nibh purus, eget convallis erat efficitur eget.

Read More

Awesome Features1111

This is description for slide three1111

Read More

From the Blog

BTK inhibitor Velexbru approved new indications: treatment of two kinds of malignant lymphoma, the total remission rate is 90%

Ono Pharmaceutical recently announced that its BTK inhibitor Velexbru (tirabrutinib hydrochloride, 80mg tablet) has been approved in Japan for the treatment of Fahrenheit macroglobulinemia (WM) and lymphocytic lymphoma (LPL). Velexbru is a highly […]

Read More →